{
    "clinical_study": {
        "@rank": "95595", 
        "arm_group": [
            {
                "arm_group_label": "700 \u03bcg NOMAC/300 \u03bcg E2", 
                "arm_group_type": "Experimental", 
                "description": "Administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days"
            }, 
            {
                "arm_group_label": "900 \u03bcg NOMAC/300 \u03bcg E2", 
                "arm_group_type": "Experimental", 
                "description": "Administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days"
            }, 
            {
                "arm_group_label": "100 \u03bcg ENG/300 \u03bcg E2", 
                "arm_group_type": "Experimental", 
                "description": "Administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days"
            }, 
            {
                "arm_group_label": "125 \u03bcg ENG/300 \u03bcg E2", 
                "arm_group_type": "Experimental", 
                "description": "Administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days"
            }
        ], 
        "brief_summary": {
            "textblock": "The study investigates four vaginal ring groups with respect to relief of primary\n      dysmenorrhea, and should identify at least one vaginal ring that shows clinically relevant\n      treatment efficacy in relief of primary dysmenorrhea."
        }, 
        "brief_title": "A Study to Evaluate the Effect of Vaginal Rings on Primary Dysmenorrhea (P08257/MK-8175A/MK-8342B-057)", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": "Dysmenorrhea", 
        "condition_browse": {
            "mesh_term": "Dysmenorrhea"
        }, 
        "detailed_description": {
            "textblock": "The study investigates four vaginal ring groups with respect to relief of primary\n      dysmenorrhea, and should identify at least one vaginal ring that shows clinically relevant\n      treatment efficacy in relief of primary dysmenorrhea. The intake of ibuprofen rescue\n      medication and the impact on daily life is investigated: change from baseline data of these\n      two variables will be compared between each of the four active ring groups, separately, and\n      the placebo ring group. Furthermore, the study assesses the measurement characteristics and\n      psychometric properties of a newly developed Dysmenorrhea Daily Dairy. Vaginal bleeding\n      pattern and general safety and tolerability will also be evaluated."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Body mass index (BMI) \u226518 and \u226435\n\n          -  Established diagnosis of primary dysmenorrhea\n\n          -  If of child-bearing potential must agree to use condoms for contraception during the\n             entire screening period, treatment period, and post-treatment period until the final\n             study visit, unless she or her partner are surgically sterilized\n\n          -  Agree to stop using hormonal contraceptive (combined or progestin-only), or a non\n             hormonal intrauterine device (IUD)\n\n          -  Regular menstrual cycles ranging from 24 to 35 days in length\n\n        Exclusion Criteria:\n\n          -  Any of the following contraindications to the use of contraceptive steroids\n             including: presence or a history of venous or arterial thrombotic/thromboembolic\n             events or cerebrovascular accident (stroke, history of migraine with focal\n             neurological symptoms, diabetes mellitus with vascular involvement, severe or\n             multiple risk factor(s) for venous or arterial thrombosis, severe dyslipoproteinemia,\n             severe hypertension, pancreatitis or a history thereof if associated with severe\n             hypertriglyceridaemia, presence or history of severe hepatic (liver) disease,\n             including benign or malignant tumors, known or suspected sex steroid-influenced\n             malignancies, and/or undiagnosed vaginal bleeding\n\n          -  Pregnant or breastfeeding\n\n          -  Secondary dysmenorrhea\n\n          -  Has not had spontaneous menstruation following a delivery or abortion\n\n          -  Participated in an investigational drug study within 30 days\n\n          -  History of malignancy \u22645 years\n\n          -  Documented abnormal cervical smear result within 6 months\n\n          -  Use of recreational or illicit drugs\n\n          -  Consumes >2 alcoholic drinks per day or >14 alcoholic drinks per week, or engages in\n             binge drinking\n\n          -  Allergy/sensitivity to ibuprofen, or any contraindication to its use, or has\n             experienced asthma, urticaria, or allergic-type reactions after taking aspirin, or\n             other nonsteroidal anti inflammatory drugs\n\n          -  Has been sterilized using a fallopian tube occlusion device\n\n          -  Is receiving, or has received sex hormones for any purpose other than contraception\n             within 2 months or injectable hormonal contraception within 6 months"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "439", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01670656", 
            "org_study_id": "P08257", 
            "secondary_id": [
                "2012-002449-40", 
                "MK-8175A/MK-8342B-057"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "700 \u03bcg NOMAC/300 \u03bcg E2", 
                    "900 \u03bcg NOMAC/300 \u03bcg E2"
                ], 
                "description": "Either 700 or 900 \u03bcg NOMAC and 300 \u03bcg E2 intravaginal ring for two 28-day cycles", 
                "intervention_name": "Nomegestrol acetate contraceptive vaginal ring (NOMAC-CVR)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "SCH900121", 
                    "MK-8175A"
                ]
            }, 
            {
                "arm_group_label": [
                    "100 \u03bcg ENG/300 \u03bcg E2", 
                    "125 \u03bcg ENG/300 \u03bcg E2"
                ], 
                "description": "Either 100 or 125 \u03bcg ENG and 300 \u03bcg E2, intravaginally for two 28-day cycles", 
                "intervention_name": "Etonogestrel containing contraceptive vaginal ring (ENG-CVR)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "SCH900432", 
                    "MK-8342B"
                ]
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo to match vaginal ring, intravaginally for two 28-day cycles", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "700 \u03bcg NOMAC/300 \u03bcg E2", 
                    "900 \u03bcg NOMAC/300 \u03bcg E2", 
                    "100 \u03bcg ENG/300 \u03bcg E2", 
                    "125 \u03bcg ENG/300 \u03bcg E2", 
                    "Placebo"
                ], 
                "description": "Ibuprofen 400 mg will be dispensed throughout the entire study as needed as rescue medication for treating menstrual cramping pain. The maximum daily ibuprofen dose is 3200 mg (8 tablets)", 
                "intervention_name": "Ibuprofen", 
                "intervention_type": "Drug", 
                "other_name": "Motrin"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Contraceptive Agents", 
                "3-keto-desogestrel", 
                "Megestrol", 
                "Ibuprofen"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "October 18, 2013", 
        "number_of_arms": "5", 
        "official_title": "A Multicenter, Randomized, Partially Blinded, Placebo-controlled Clinical Trial to Evaluate the Effect on Primary Dysmenorrhea of Vaginal Rings With an Average Daily Release of 700 \u03bcg Nomegestrol Acetate (NOMAC) and 300 \u03bcg Estradiol (E2), or 900 \u03bcg Nomegestrol Acetate (NOMAC) and 300 \u03bcg Estradiol (E2), or 100 \u03bcg Etonogestrel (ENG) and 300 \u03bcg E2, or 125 \u03bcg Etonogestrel (ENG) and 300 \u03bcg E2. Protocol MK-8175A/MK-8342B 057 (Abbreviated as P057), Also Known as SCH900121/SCH900432 08257 (Abbreviated as P08257)", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change in Mean Menstrual Cramping Pain Score", 
            "safety_issue": "No", 
            "time_frame": "Baseline to End of Cycle 2 (Day 56)"
        }, 
        "removed_countries": {
            "country": [
                "Australia", 
                "Belgium", 
                "Chile", 
                "Denmark", 
                "Mexico", 
                "Netherlands", 
                "New Zealand", 
                "Poland", 
                "South Africa", 
                "Colombia", 
                "Germany", 
                "Norway", 
                "Spain", 
                "Sweden"
            ]
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01670656"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in Mean Total Impact Score", 
                "safety_issue": "No", 
                "time_frame": "Baseline to End of Cycle 2 (Day 56)"
            }, 
            {
                "measure": "Change in Number of Ibuprofen Tablets", 
                "safety_issue": "No", 
                "time_frame": "Baseline  to End of Cycle 2 (Day 56)"
            }, 
            {
                "measure": "Change in Number of Days of Ibuprofen Intake", 
                "safety_issue": "No", 
                "time_frame": "Baseline to End of Cycle 2 (Day 56)"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}